accountDomain Therapeutics grants Prexton option to develop mGluR4 PAMs for ... Healthcare Global France-based Biopharmaceutical Company Domain Therapeutics has granted an exclusive option to Prexton Therapeuticsto license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allostric Modulator (PAM) drugs targeting Parkinson's ...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Domain Therapeutics grants Prexton option to develop mGluR4 PAMs for ... - Healthcare Global
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account